LIVIA CAROLINE MARIANO COMPTE
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
article 0 Citação(ões) na Scopus GVHD treatment with extracorporeal photopheresis in Brazil: a national survey(2022) FATOBENE, Giancarlo; CORDEIRO, Ana; MARIANO, Livia; SILVA, Marcia; BOUZAS, Luis; HAMERSCHLAK, Nelson; MACEDO, Maria Cristina; PETTA, Alessandra; FUNKE, Vaneuza; NOVIS, Yana; FLOWERS, Mary E.; ROCHA, Vanderson- Prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation comparing tuberculin skin test and interferon-gamma release assay(2023) CASTRO-LIMA, Victor A. C.; SANTOS, Ana Paula T.; MUSQUEIRA, Priscila T.; MALUF, Natalya Z.; RAMOS, Jessica F.; MARIANO, Livia; ROCHA, Vanderson; COSTA, Silvia F.The aim of this study was to evaluate the prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation candidates, using tuberculin skin test and QuantiFERON-TB Gold-Plus, in a high-burden tuberculosis country. Adult candidates for hematopoietic stem cell transplantation performed both tests before and those submitted to transplantation were followed up for 12 months. The prevalence of latent Mycobacterium tuberculosis infection was 17.1% and a moderate agreement between QuantiFERON-TB Gold-Plus and tuberculin skin test was observed in this population. Previous tuberculosis exposure was a risk factor for latent Mycobacterium tuberculosis infection. No cases of tuberculosis were diagnosed during follow-up period.
- Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival(2023) VIGORITO, Afonso Celso; MIRANDA, Eliana Cristina Martins; COLTURATO, Vergilio Antonio Rensi; FUNKE, Vaneuza Araujo Moreira; FATOBENE, Giancarlo; MARIANO, Livia; MACEDO, Maria Cristina Martins de Almeida; RIBEIRO, Lorena Bedotti; DAUDT, Liane Esteves; MOREIRA, Maria Claudia Rodrigues; BONFIM, Carmem; COLELLA, Marcos Paulo; SEBER, Adriana; RODRIGUES, Morgani; DUARTE, Fernando Barroso; MARTIN, Paul J.; FLOWERS, Mary E. D.Failure-free survival (FFS), defined as the absence of new systemic treatment, recurrence of original malignancy and mortality not associated with recurrence after allogeneic hematopoietic stem cell transplantation (HCT), is a robust clinical measure to interpret results of initial systemic treatment of chronic graft-versus-host disease (cGVHD). We evaluate FFS after initial treatment of cGVHD in a mixed-race cohort from a resource-constrained country. This retrospective study included 354 consecutive patients after their first HCT between January 2014 and August 2020, who received initial systemic treatment for moderate or severe cGVHD at 13 Brazilian centers. Cox regression models were used to identify risk factors for treatment failure. The overall median follow-up among survivors was 28 months (range 1-71) after initial treatment. FFS was 89% at 6 months, 71% at 1 year and 52% at 2 years. New systemic treatment was the major cause of failure. In multivariable models, prior grades II-IV acute GVHD, a National Institutes of Health severity score of 3 in liver, gastrointestinal tract or lung involvement, and onset of initial treatment of cGVHD within 12 months after transplantation were all associated with an increased risk of treatment failure. Our results could serve as a benchmark for the design of future clinical trials evaluating initial treatment of cGVHD in resource-constrained locations.
- Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies(2023) FATOBENE, Giancarlo; MARIANO, Livia; VOLT, Fernanda; MOREIRA, Frederico; CONELISSEN, Jan; FURST, Sabine; DAGUINDAU, Etienne; SIRVENT, Anne; LATOUR, Regis Peffault de; RAFIL, Hanadi; RIVERA-FRANCO, Monica M.; KENZEY, Chantal; SCIGLIUOLO, Graziana Maria; CAPPELLI, Barbara; RUGGERI, Annalisa; GLUCKMAN, Eliane; ROCHA, VandersonIn single unrelated cord blood transplantation (UCBT), an increasing number of HLA allele mismatches (MM) has been associated with inferior overall survival (OS) and attributed to higher transplant-related mortality (TRM). Previous studies on the role of allele-level HLA matching after double UCBT (dUCBT) showed conflicting results. In this study, we report the impact of allele-level HLA matching on the outcomes of a large dUCBT cohort. We included 963 adults with hematologic malignancies, with available allele-level HLA matching at HLAA, -B, -C, and -DRB1, receiving dUCBT between 2006 to 2019. Assignment of donor-recipient HLA match was performed considering the unit with the highest disparity with the recipient. Three hundred ninety-two patients received dUCBT with 0 to 3 MM and 571 with >4 allele MM. For recipients of dUCBT with 0 to 3 MM, day-100 and 4-year TRM were 10% and 23%, respectively, compared with 16% and 36% for those with >4 MM. A higher degree of allele MM was also associated with the worse neutrophil recovery and lower incidence of relapse; no significant effect on graft-versus-host disease was observed. Patients receiving units with 0 to 3 MM had a 4-year OS of 54% compared with 43% for those receiving units with >4 MM. The inferior OS associated with higher HLA disparity was only partially mitigated by increased total nucleated cell doses. Our results confirm that allele-level HLA typing is a significant factor for OS after dUCBT, and units with >4 MM (<4/8 HLA-matched) should be avoided if possible.